{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:10:41Z","timestamp":1779203441469,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI093269"],"award-info":[{"award-number":["R01 AI093269"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37 AI058736"],"award-info":[{"award-number":["R37 AI058736"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40273-026-01595-3","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:11:03Z","timestamp":1772820663000},"page":"653-664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Component Clinical and Cost Outcomes Complementing Value of Information: Case Study of a Tuberculosis Diagnostics Clinical Trial"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6095-8494","authenticated-orcid":false,"given":"Pamela","family":"Pei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Qoshe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grady","family":"Florance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6130-2286","authenticated-orcid":false,"given":"Ankur","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton C.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Freedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-3290","authenticated-orcid":false,"given":"A. David","family":"Paltiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1832-2193","authenticated-orcid":false,"given":"Krishna P.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"1595_CR1","unstructured":"Building the evidence to inform clinical practice worldwide: in conversation with Laurent Billot | The George Institute for Global Health. 19 May 2022. https:\/\/www.georgeinstitute.org\/news-and-media\/news\/building-the-evidence-to-inform-clinical-practice-worldwide-in-conversation-with-laurent-billot. Accessed 14 July 2025."},{"issue":"11","key":"1595_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","volume":"178","author":"TJ Moore","year":"2018","unstructured":"Moore TJ, Zhang H, Anderson G, Alexander GC. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med. 2018;178(11):1451\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2018.3931.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1595_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001882","volume":"12","author":"C Minelli","year":"2015","unstructured":"Minelli C, Baio G. Value of information: a tool to improve research prioritization and reduce waste. PLoS Med. 2015;12(9):e1001882. https:\/\/doi.org\/10.1371\/journal.pmed.1001882.","journal-title":"PLoS Med"},{"issue":"2","key":"1595_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40273-014-0219-x","volume":"33","author":"ECF Wilson","year":"2015","unstructured":"Wilson ECF. A practical guide to value of information analysis. Pharmacoeconomics. 2015;33(2):105\u201321. https:\/\/doi.org\/10.1007\/s40273-014-0219-x.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1595_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick E, Steuten L, Knies S, et al. Value of information analysis for research decisions\u2014an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23(2):139\u201350. https:\/\/doi.org\/10.1016\/j.jval.2020.01.001.","journal-title":"Value Health"},{"issue":"10","key":"1595_CR6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA"},{"issue":"7","key":"1595_CR7","doi-asserted-by":"publisher","first-page":"e2077","DOI":"10.1093\/cid\/ciaa1698","volume":"73","author":"KP Reddy","year":"2021","unstructured":"Reddy KP, Denkinger CM, Broger T, et al. Cost-effectiveness of a novel lipoarabinomannan test for tuberculosis in patients with human immunodeficiency virus. Clin Infect Dis. 2021;73(7):e2077\u201385. https:\/\/doi.org\/10.1093\/cid\/ciaa1698.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1595_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hec.853","volume":"13","author":"RH Chapman","year":"2004","unstructured":"Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ. 2004;13(5):429\u201336. https:\/\/doi.org\/10.1002\/hec.853.","journal-title":"Health Econ"},{"issue":"10053","key":"1595_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2016","unstructured":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545\u2013602. https:\/\/doi.org\/10.1016\/S0140-6736(16)31678-6.","journal-title":"Lancet"},{"issue":"10053","key":"1595_CR10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459\u2013544. https:\/\/doi.org\/10.1016\/S0140-6736(16)31012-1.","journal-title":"Lancet"},{"issue":"11","key":"1595_CR11","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2214-109X(16)30265-0","volume":"4","author":"NA Menzies","year":"2016","unstructured":"Menzies NA, Gomez GB, Bozzani F, et al. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. Lancet Glob Health. 2016;4(11):e816\u201326. https:\/\/doi.org\/10.1016\/S2214-109X(16)30265-0.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1595_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/23814683231198873","volume":"8","author":"PP Pei","year":"2023","unstructured":"Pei PP, Fitzmaurice KP, Le MH, et al. The value-of-information and value-of-implementation from clinical trials of diagnostic tests for HIV-associated tuberculosis: a modeling analysis. MDM Policy Pract. 2023;8(2):23814683231198873. https:\/\/doi.org\/10.1177\/23814683231198873.","journal-title":"MDM Policy Pract"},{"issue":"5","key":"1595_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/0272989X16686766","volume":"37","author":"SE Grimm","year":"2017","unstructured":"Grimm SE, Dixon S, Stevens JW. Assessing the expected value of research studies in reducing uncertainty and improving implementation dynamics. Med Decis Mak. 2017;37(5):523\u201333. https:\/\/doi.org\/10.1177\/0272989X16686766.","journal-title":"Med Decis Mak"},{"issue":"3","key":"1595_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/0272989X15614814","volume":"36","author":"L Andronis","year":"2016","unstructured":"Andronis L, Barton PM. Adjusting estimates of the expected value of information for implementation: theoretical framework and practical application. Med Decis Mak. 2016;36(3):296\u2013307. https:\/\/doi.org\/10.1177\/0272989X15614814.","journal-title":"Med Decis Mak"},{"key":"1595_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1837-z","volume":"16","author":"A Gupta-Wright","year":"2016","unstructured":"Gupta-Wright A, Fielding KL, van Oosterhout JJ, et al. Rapid urine-based screening for tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (the STAMP trial): study protocol for a randomised controlled trial. BMC Infect Dis. 2016;16:501. https:\/\/doi.org\/10.1186\/s12879-016-1837-z.","journal-title":"BMC Infect Dis"},{"key":"1595_CR16","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.13112.2","volume":"4","author":"DN Singhroy","year":"2020","unstructured":"Singhroy DN, MacLean E, Kohli M, et al. Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV\/AIDS burden: current landscape and barriers. Gates Open Res. 2020;4:24. https:\/\/doi.org\/10.12688\/gatesopenres.13112.2.","journal-title":"Gates Open Res"},{"key":"1595_CR17","unstructured":"World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update 2019. Published online 2019. https:\/\/iris.who.int\/handle\/10665\/329479. Accessed 14 July 2025."},{"issue":"8","key":"1595_CR18","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1473-3099(19)30001-5","volume":"19","author":"T Broger","year":"2019","unstructured":"Broger T, Sossen B, du Toit E, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2019;19(8):852\u201361. https:\/\/doi.org\/10.1016\/S1473-3099(19)30001-5.","journal-title":"Lancet Infect Dis"},{"issue":"10144","key":"1595_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0140-6736(18)31267-4","volume":"392","author":"A Gupta-Wright","year":"2018","unstructured":"Gupta-Wright A, Corbett EL, van Oosterhout JJ, et al. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. Lancet. 2018;392(10144):292\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(18)31267-4.","journal-title":"Lancet"},{"issue":"2","key":"1595_CR20","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2214-109X(18)30436-4","volume":"7","author":"KP Reddy","year":"2019","unstructured":"Reddy KP, Gupta-Wright A, Fielding KL, et al. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. Lancet Glob Health. 2019;7(2):e200\u20138. https:\/\/doi.org\/10.1016\/S2214-109X(18)30436-4.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"1595_CR21","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.19.1.20714","volume":"19","author":"N Ford","year":"2016","unstructured":"Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714. https:\/\/doi.org\/10.7448\/IAS.19.1.20714.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"1595_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09895-7","volume":"7","author":"AD Kerkhoff","year":"2017","unstructured":"Kerkhoff AD, Barr DA, Schutz C, et al. Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays. Sci Rep. 2017;7(1):10931. https:\/\/doi.org\/10.1038\/s41598-017-09895-7.","journal-title":"Sci Rep"},{"issue":"11","key":"1595_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013901","volume":"5","author":"HS Cox","year":"2010","unstructured":"Cox HS, McDermid C, Azevedo V, et al. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS\u00a0One. 2010;5(11):e13901. https:\/\/doi.org\/10.1371\/journal.pone.0013901.","journal-title":"PLoS\u00a0One"},{"key":"1595_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijid.2018.08.005","volume":"75","author":"TH Boyles","year":"2018","unstructured":"Boyles TH, Griesel R, Stewart A, Mendelson M, Maartens G. Incremental yield and cost of urine determine TB-LAM and sputum induction in seriously ill adults with HIV. Int J Infect Dis. 2018;75:67\u201373. https:\/\/doi.org\/10.1016\/j.ijid.2018.08.005.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"1595_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/QAI.0000000000000970","volume":"72","author":"W Katagira","year":"2016","unstructured":"Katagira W, Walter ND, den Boon S, et al. Empiric TB treatment of severely ill patients with HIV and presumed pulmonary TB improves survival. JAIDS J Acquir Immune Defic Syndr. 2016;72(3):297\u2013303. https:\/\/doi.org\/10.1097\/QAI.0000000000000970.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"2","key":"1595_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1513\/AnnalsATS.201905-418OC","volume":"17","author":"KP Reddy","year":"2020","unstructured":"Reddy KP, Horsburgh CR, Wood R, et al. Shortened tuberculosis treatment for people with HIV in South Africa. A model-based evaluation and cost-effectiveness analysis. Ann Am Thorac Soc. 2020;17(2):202\u201311. https:\/\/doi.org\/10.1513\/AnnalsATS.201905-418OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"1595_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.5588\/ijtld.12.0505","volume":"17","author":"MM Claassens","year":"2013","unstructured":"Claassens MM, du Toit E, Dunbar R, et al. Tuberculosis patients in primary care do not start treatment. What role do health system delays play? Int J Tuberc Lung Dis. 2013;17(5):603\u20137. https:\/\/doi.org\/10.5588\/ijtld.12.0505.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"1595_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037634","volume":"7","author":"DJ Pepper","year":"2012","unstructured":"Pepper DJ, Marais S, Bhaijee F, Wilkinson RJ, De Azevedo V, Meintjes G. Assessment at antiretroviral clinics during TB treatment reduces loss to follow-up among HIV-infected patients. PLoS\u00a0One. 2012;7(6):e37634. https:\/\/doi.org\/10.1371\/journal.pone.0037634.","journal-title":"PLoS\u00a0One"},{"issue":"9","key":"1595_CR29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/QAD.0b013e3283390dd1","volume":"24","author":"SD Lawn","year":"2010","unstructured":"Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS. 2010;24(9):1323\u20138. https:\/\/doi.org\/10.1097\/QAD.0b013e3283390dd1.","journal-title":"AIDS"},{"issue":"8","key":"1595_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/QAD.0b013e3283522d47","volume":"26","author":"JR Andrews","year":"2012","unstructured":"Andrews JR, Lawn SD, Rusu C, et al. <article-title update=\"added\">The cost-effectiveness of routine tuberculosis screening with Xpert MTB\/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012;26(8):987\u201395. https:\/\/doi.org\/10.1097\/QAD.0b013e3283522d47.","journal-title":"AIDS"},{"issue":"4","key":"1595_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/01.qai.0000225729.79610.b7","volume":"42","author":"CB Holmes","year":"2006","unstructured":"Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. JAIDS J Acquir Immune Defic Syndr. 2006;42(4):464. https:\/\/doi.org\/10.1097\/01.qai.0000225729.79610.b7.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"4","key":"1595_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/135965350701200416","volume":"12","author":"E Losina","year":"2007","unstructured":"Losina E, Yazdanpanah Y, Deuffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in C\u00f4te D\u2019ivoire. Antivir Ther. 2007;12(4):543\u201351.","journal-title":"Antivir Ther"},{"issue":"1","key":"1595_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054587","volume":"8","author":"A Pooran","year":"2013","unstructured":"Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS\u00a0One. 2013;8(1):e54587. https:\/\/doi.org\/10.1371\/journal.pone.0054587.","journal-title":"PLoS\u00a0One"},{"key":"1595_CR34","unstructured":"Clinton Health Access Initiative. 2016 Antiretroviral (ARV) CHAI reference price list. https:\/\/clintonhealthaccess.org\/wp-content\/uploads\/2016\/11\/2016-CHAI-ARV-Reference-Price-List_FINAL.pdf. Accessed 14 July 2025."},{"key":"1595_CR35","unstructured":"National Health Laboratory Service. National Health Laboratory Service. www.nhls.ac.za. Accessed 14 July 2025."},{"issue":"3","key":"1595_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192991","volume":"13","author":"H Maheswaran","year":"2018","unstructured":"Maheswaran H, Petrou S, Cohen D, et al. Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: a prospective hospital cohort study in Malawi. PLoS\u00a0One. 2018;13(3):e0192991. https:\/\/doi.org\/10.1371\/journal.pone.0192991.","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"1595_CR37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.5588\/ijtld.12.0627","volume":"17","author":"D Sun","year":"2013","unstructured":"Sun D, Dorman S, Shah M, et al. Cost-utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults. Int J Tuberc Lung Dis. 2013;17(4):552\u20138. https:\/\/doi.org\/10.5588\/ijtld.12.0627.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1595_CR38","unstructured":"Statistics South Africa. Public healthcare: how much per person? 2 October 2017. https:\/\/www.statssa.gov.za\/?p=10548. Accessed 14 July 2025."},{"key":"1595_CR39","unstructured":"Padarath A, Barron P, editors. South African Health Review 2017, 20th edition. http:\/\/www.hst.org.za\/publications\/Pages\/HSTSouthAfricanHealthReview.aspx. Accessed 14 July 2025."},{"issue":"5","key":"1595_CR40","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/heapol\/czz152","volume":"35","author":"IP Edoka","year":"2020","unstructured":"Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020;35(5):546\u201355. https:\/\/doi.org\/10.1093\/heapol\/czz152.","journal-title":"Health Policy Plan"},{"issue":"10","key":"1595_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186496","volume":"12","author":"G Meyer-Rath","year":"2017","unstructured":"Meyer-Rath G, van Rensburg C, Larson B, Jamieson L, Rosen S. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: evidence from the South African HIV Investment Case. PLoS\u00a0One. 2017;12(10):e0186496. https:\/\/doi.org\/10.1371\/journal.pone.0186496.","journal-title":"PLoS\u00a0One"},{"issue":"6","key":"1595_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000964","volume":"3","author":"J Ochalek","year":"2018","unstructured":"Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health. 2018;3(6):e000964. https:\/\/doi.org\/10.1136\/bmjgh-2018-000964.","journal-title":"BMJ Glob Health"},{"issue":"6","key":"1595_CR43","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11(6):e833\u201342. https:\/\/doi.org\/10.1016\/S2214-109X(23)00162-6.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"1595_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1586\/14737167.4.6.599","volume":"4","author":"RM Klok","year":"2004","unstructured":"Klok RM, Postma MJ. Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant. Expert Rev Pharmacoecon Outcomes Res. 2004;4(6):599\u2013601. https:\/\/doi.org\/10.1586\/14737167.4.6.599.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"1595_CR45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/15284336.2015.1123942","volume":"16","author":"PP Pei","year":"2015","unstructured":"Pei PP, Weinstein MC, Li XC, et al. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Clin Trials. 2015;16(6):207\u201318. https:\/\/doi.org\/10.1080\/15284336.2015.1123942.","journal-title":"HIV Clin Trials"},{"issue":"12","key":"1595_CR46","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jval.2020.06.013","volume":"23","author":"X Zang","year":"2020","unstructured":"Zang X, Jalal H, Krebs E, et al. Prioritizing additional data collection to reduce decision uncertainty in the HIV\/AIDS response in 6 US cities: a value of information analysis. Value Health. 2020;23(12):1534\u201342. https:\/\/doi.org\/10.1016\/j.jval.2020.06.013.","journal-title":"Value Health"},{"issue":"5","key":"1595_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001031","volume":"3","author":"A Micieli","year":"2014","unstructured":"Micieli A, Bennell MC, Pham B, Krahn M, Singh SM, Wijeysundera HC. Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation. J Am Heart Assoc. 2014;3(5):e001031. https:\/\/doi.org\/10.1161\/JAHA.114.001031.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"1595_CR48","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jval.2019.05.004","volume":"22","author":"NR Kunst","year":"2019","unstructured":"Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A value of information analysis of research on the 21-gene assay for breast cancer management. Value Health. 2019;22(10):1102\u201310. https:\/\/doi.org\/10.1016\/j.jval.2019.05.004.","journal-title":"Value Health"},{"issue":"5","key":"1595_CR49","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1111\/add.15773","volume":"117","author":"A Adamson","year":"2022","unstructured":"Adamson A, Portas L, Accordini S, et al. Communication of personalised disease risk by general practitioners to motivate smoking cessation in England: a cost-effectiveness and research prioritisation study. Addiction. 2022;117(5):1438\u201349. https:\/\/doi.org\/10.1111\/add.15773.","journal-title":"Addiction"},{"issue":"8","key":"1595_CR50","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jval.2022.03.016","volume":"25","author":"SW Dijk","year":"2022","unstructured":"Dijk SW, Krijkamp EM, Kunst N, Gross CP, Wong JB, Hunink MGM. Emerging therapies for COVID-19: the value of information from more clinical trials. Value Health. 2022;25(8):1268\u201380. https:\/\/doi.org\/10.1016\/j.jval.2022.03.016.","journal-title":"Value Health"},{"issue":"9","key":"1595_CR51","doi-asserted-by":"publisher","first-page":"662","DOI":"10.7326\/0003-4819-151-9-200911030-00011","volume":"151","author":"AL Nelson","year":"2009","unstructured":"Nelson AL, Cohen JT, Greenberg D, Kent DM. Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med. 2009;151(9):662\u20137. https:\/\/doi.org\/10.7326\/0003-4819-151-9-200911030-00011.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1595_CR52","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2018.10624","volume":"320","author":"A Pandya","year":"2018","unstructured":"Pandya A. Improving health care value by considering cost-effectiveness\u2014reply. JAMA. 2018;320(12):1287\u20138. https:\/\/doi.org\/10.1001\/jama.2018.10624.","journal-title":"JAMA"},{"issue":"11","key":"1595_CR53","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jval.2019.06.014","volume":"22","author":"R Baltussen","year":"2019","unstructured":"Baltussen R, Marsh K, Thokala P, et al. Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward. Value Health. 2019;22(11):1283\u20138. https:\/\/doi.org\/10.1016\/j.jval.2019.06.014.","journal-title":"Value Health"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01595-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01595-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01595-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:41:14Z","timestamp":1779201674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01595-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1595"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01595-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PP and KPR contributed to the conception and design of this work. PP, LQ, and GF contributed to data acquisition and analysis. All authors contributed to data interpretation. PP, LQ, GF, and KPR drafted the manuscript. All other authors contributed to revising the manuscript critically for important intellectual content. All authors approve of the final version of the manuscript submitted for publication. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}